2015 Michigan Proposal 1

FTS International Announces March 3, 2022 Special Meeting Results

Retrieved on:

Thursday, March 3, 2022

Oil, Gas, Energy, Risk, Private Securities Litigation Reform Act, Industry, Forward-looking statement, Security (finance), Annual report, U.S. Securities and Exchange Commission, 2015 Michigan Proposal 1, Special, COVID-19, Communication, Adjournment, Risk management

Although Proposal 3 was approved, the adjournment of the Special Meeting was not necessary because FTSIs stockholders approved Proposal 1.

Key Points:

Although Proposal 3 was approved, the adjournment of the Special Meeting was not necessary because FTSIs stockholders approved Proposal 1.
This communication contains forward-looking statements within the Private Securities Litigation Reform Act of 1995.
Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict.
Accordingly, actual results may differ materially from those contemplated by these forward-looking statements.

Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

Retrieved on:

Friday, December 17, 2021

MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 2021, it plans to continue to explore additional options to maximize stockholder value. The Company’s Proposal 2 to authorize a reverse stock split, a condition to consummating the Company’s agreed upon merger with Biosight, was not approved at the meeting.

Key Points:

The merger proposal received the requisite stockholder votes by a clear majority of votes cast and, as a result, has passed.
Approval of a reverse stock split as contemplated by Proposal 2 is a condition for completing the merger of Advaxis and Biosight.
Advaxis, Inc.is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
Completion of the proposed transactions is subject to approval by the stockholders of Advaxis, Inc. and certain other conditions.

iBio Announces Partial Adjournment of Annual Meeting to December 22

Retrieved on:

Friday, December 10, 2021

BRYAN, Texas, Dec. 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its annual meeting of stockholders (the "Annual Meeting") scheduled for and convened yesterday has been partially adjourned to December 22, 2021 at 9:00 a.m. Eastern Time.

Key Points:

The Companys stockholders also approved Proposal 6 (adjournment of the Annual Meeting) for the purpose of continuing to solicit votes in favor of Proposal 4 (reverse stock split) and Proposal 5 (authorized share decrease).
With over 60% of all shares voted, iBio stockholders are in favor of the reverse split and authorized share decrease by approximately a 2-to-1 margin.
Additionally, both of the leading proxy advisory firms (Glass Lewis and ISS) have recommended that stockholders vote FOR the proposals.
iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases.

Progressive Care Inc. Announces Results of Special Meeting

Retrieved on:

Thursday, December 9, 2021

Common stock, Company, GLOBE, Preferred stock, CEO, Board, Goal, Mark (given name), Special, Social media, 2015 Michigan Proposal 1, Holding company, Security (finance)

MIAMI, FLORIDA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- On December 3, 2021, Progressive Care Inc. (the “Company” or “Progressive Care”) held a special meeting of its stockholders (the “Special Meeting”). The record date for stockholders entitled to notice of, and to vote at, the Special Meeting was November 3, 2021. At the close of business on that date, the Company had 535,430,294 shares of common stock, par value $0.0001 (“Common Stock”) outstanding and 51 shares of Series A Preferred Stock (“Preferred Stock”) outstanding, and entitled to be voted at the Special Meeting. At the Special Meeting, the following three proposals were submitted to the Company’s stockholders:

Key Points:

MIAMI, FLORIDA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- On December 3, 2021, Progressive Care Inc. (the Company or Progressive Care) held a special meeting of its stockholders (the Special Meeting).
The record date for stockholders entitled to notice of, and to vote at, the Special Meeting was November 3, 2021.
At the close of business on that date, the Company had 535,430,294 shares of common stock, par value $0.0001 (Common Stock) outstanding and 51 shares of Series A Preferred Stock (Preferred Stock) outstanding, and entitled to be voted at the Special Meeting.
At the Special Meeting, the following three proposals were submitted to the Companys stockholders:
1.

Sachem Capital Adjourns Meeting of Shareholders Until November 24, 2021

Retrieved on:

Thursday, November 4, 2021

U.S. Securities and Exchange Commission, Annual Meetings of the International Monetary Fund and the World Bank Group, Rehabilitation, Proposal 2, Annual, Acquisition, Internet, Company, GLOBE, Annual general meeting, NYSE, 2015 Michigan Proposal 1, REIT, Animal

BRANFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) today announced that its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 2, was reconvened on November 3, 2021 and adjourned and rescheduled for Wednesday, November 24, 2021 at 10:00 a.m., Eastern Standard Time.

Key Points:

The Company adjourned the Annual Meeting, held on October 13, 2021, to November 3, 2021, with respect to Proposal 2 to give itself additional time to solicit proxies with respect to that proposal.
The Company has determined that a further adjournment is necessary to allow shareholders who have not yet voted additional time to vote.
The Annual Meeting will resume virtually via the internet at https://meetnow.global/MUUP4LY on Wednesday, November 24, 2021 at 10:00 a.m., Eastern Standard Time.
Sachem Capital Corp. specializes in originating, underwriting, funding, servicing, and managing a portfolio of first mortgage loans.

SigmaTron International, Inc. Announces Results of Special Meeting

Retrieved on:

Friday, October 22, 2021

The Company did not change the record date for the Special Meeting.

Key Points:

The Company did not change the record date for the Special Meeting.
Only stockholders of record at the close of business on August 24, 2021 were entitled to vote at the reconvened Special Meeting.
Regarding Proposal 2 to approve the adoption of the SigmaTron International, Inc. 2021 Employee Stock Option Plan, 83.4% of the votes were cast in favor of the Proposal.
Because these forward-looking statements involve risks and uncertainties, the Companys plans, actions and actual results could differ materially.

Sachem Capital Shareholders Re-elect Board

Retrieved on:

Wednesday, October 13, 2021

Annual general meeting, Internet, Annual Meetings of the International Monetary Fund and the World Bank Group, Rehabilitation, Security (finance), U.S. Securities and Exchange Commission, NYSE, REIT, File, Annual, GLOBE, Securities & Exchange Commission of Pakistan, Company, 2015 Michigan Proposal 1, Acquisition, Proposal 2, Animal

BRANFORD, Conn., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) today announced that its 2021 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled for Wednesday, October 13, 2021 at 10:00 a.m. Eastern Daylight Saving Time, was convened on Proposals 1 (election of directors), 3 (advisory approval of the appointment of auditors) and 4 (advisory approval of executive compensation), each as set forth in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on September 10, 2021 (the “Proxy Statement”), all of which were approved. Details of the vote will be available in the Company’s Form 8-K reporting the voting results of the Annual Meeting to be filed with the Securities and Exchange Commission and will be available on the Company’s website upon filing.

Key Points:

The Company adjourned the Annual Meeting with respect to Proposal 2, to amend its certificate of incorporation to increase the number of authorized capital shares of the Company.
The adjournment will allow shareholders additional time to vote and allow the company to continue to solicit additional votes on Proposal 2.
Shareholders of record may vote their shares by calling InvestorCom at (877) 972-0090.
Sachem Capital Corp. specializes in originating, underwriting, funding, servicing, and managing a portfolio of first mortgage loans.

Lydall Announces September 14, 2021 Special Meeting Results

Retrieved on:

Tuesday, September 14, 2021

U.S. Securities and Exchange Commission, Security (finance), Investment, Technology, Forward-looking statement, New York Stock Exchange, Company, Private Securities Litigation Reform Act, Risk, Annual report, 2015 Michigan Proposal 1, Adjournment, Communication, Solution, Clearlake, COVID-19, Plant, Special, Swings

Although Proposal 3 was approved, the adjournment of the Special Meeting was not necessary because Lydalls stockholders approved Proposal 1.

Key Points:

Although Proposal 3 was approved, the adjournment of the Special Meeting was not necessary because Lydalls stockholders approved Proposal 1.
Accordingly, actual results may differ materially from those contemplated by these forward-looking statements.
Lydall delivers value-added engineered materials and specialty filtration solutions that promote a cleaner, safer, and quieter world.
Lydall is a registered trademark of Lydall, Inc. in the U.S. and other countries.

Tilray Announces Adjournment of Special Meeting of Stockholders to September 10, 2021

Retrieved on:

Thursday, August 19, 2021

The Special Meeting was adjourned to September 10, 2021, at 11:00 a.m. Eastern Time.

Key Points:

The Special Meeting was adjourned to September 10, 2021, at 11:00 a.m. Eastern Time.
Irwin D. Simon, Tilrays Chairman and CEO said, We urge stockholders who have not yet voted to participate in the success of their investment in Tilray by voting FOR all proposals on the agenda for the Special Meeting.
The record date for the adjourned Special Meeting remains June 22, 2021.
Stockholders who have already voted do not need to recast their votes unless they wish to change their vote.

Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights

Retrieved on:

Thursday, August 5, 2021

ET

Key Points:

ET
MALVERN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the Company), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today reported financial results for the three and six months ended June30, 2021.
Specifically, for the second quarter of 2021 as compared to the first quarter of 2021:
ANJESO added to over 100 formularies in less than one year on the market.
In May 2021, Baudax Bio highlighted the online publication of Phase IIIb study results evaluating preoperative injection of ANJESO prior to colorectal surgery in the journal Pain Management.
Baudax Bio will host a conference call today, Thursday, August 5, 2021, at 8:00 a.m. Eastern Time, to discuss the second quarter 2021 financial results and recent corporate achievements.